58 results
8-K
EX-99.1
NMRD
Nemaura Medical Inc
14 Nov 23
Regulation FD Disclosure
4:33pm
- USA Over 100 million potential customers 1,2 Anticipate reimbursement by healthcare providers and employers Gross margins expected to be 70
8-K
EX-99.1
NMRD
Nemaura Medical Inc
13 Nov 23
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
4:15pm
to obtain reimbursement for the sensors in the UK.
Advanced development of the Company’s BEATdiabetes offering in readiness for a commercial launch
424B8
NMRD
Nemaura Medical Inc
11 Sep 23
Prospectus unintentially filed late
4:41pm
dedicated to developing user based feedback and evidence that could potentially support reimbursement in the UK.
Our Business Strategy
We intend … an application of reimbursement of the sensors and we continue to support these endeavors. We also took the following actions during the fiscal year ended
8-K
EX-99.1
xa6r2utrhb
14 Aug 23
Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update
8:30am
8-K
EX-99.1
o9yw7jdn9lu3q85jth0c
11 Aug 23
Nemaura Medical Secures $6.5m in Non-Dilutive Funding
5:07pm
POS AM
t6edn8gg mwbg
3 Aug 23
Prospectus update (post-effective amendment)
4:08pm
8-K
EX-99.1
pacowx apmdtjwr19a
14 Jul 23
Results of Operations and Financial Condition
9:18am
424B4
hrrcnph24qut8 3y
15 May 23
Prospectus supplement with pricing info
4:31pm
CORRESP
ll7vwkfvj9dk0
10 May 23
Correspondence with SEC
12:00am
DEF 14C
f51z0g
18 Apr 23
Information statement
10:26am
PRE 14C
j9h355e
7 Apr 23
Preliminary information
4:05pm
424B5
38a43ok fmwfk9
1 Apr 22
Prospectus supplement for primary offering
4:29pm